Post hoc integrated analysis of four placebo-controlled studies in men ( aged 45 years ; International Prostate Symptom Score [ IPSS ] of 13 ; maximum urinary flow rate [ Q ( max ) ] of 4 to 15 mL/s ) with BPH-LUTS randomised to tadalafil 5 mg ( 752 patients ) or placebo ( 747 ) for 12 weeks after a 4-week placebo run-in .